TY - JOUR
T1 - Podocyte injuries exacerbate mesangial proliferative glomerulonephritis
AU - Morioka, Yoshio
AU - Koike, Hiroko
AU - Ikezumi, Yohei
AU - Ito, Yumi
AU - Oyanagi, Akihisa
AU - Gejyo, Fumitake
AU - Shimizu, Fujio
AU - Kawachi, Hiroshi
N1 - Funding Information:
This work was supported by Grant-Aids for Scientific Research (C) (11671031 to H. Kawachi), Grant-Aids for Scientific Research (B) (08457286 to F. Shimizu) from the Ministry of Education, Science, Culture, Sports of Japan, Grant-Aids from the Naito Memorial Foundation (to H. Kawachi), and Tsukada Medical Foundation (to Y. Ikezumi). The authors express their gratitude to Mr. K. Adachi, Ms. M. Oba, Ms. Y. Kondo, and Ms. C. Nagasawa for their technical assistance.
PY - 2001
Y1 - 2001
N2 - Background. From the observations of morphology seen in early phases of the experimental models of the irreversible mesangial proliferative glomerulonephritis, we hypothesized that podocyte injury is one of the important factors in bringing upon irreversible glomerular alterations. To verify this hypothesis, we investigated whether podocyte injury induced by puromycin aminonucleoside (PAN) injection affects the mesangial alterations of anti-Thy 1.1 glomerulonephritis. Methods. Female Wistar rats were injected with 0.5 mg monoclonal antibody (mAb) 1-22-3 five days after the injection of 10 mg or 5 mg/100 g body weight (BW) of puromycin aminonucleoside (PAN), and sacrificed at 7 days or 8 weeks after the mAb 1-22-3 injection. Results. Consecutive injections of 10 mg/100 g BW of PAN and mAb 1-22-3 caused the irreversible mesangial alteration with persistent proteinuria (at week 8, proteinuria 100.3 ± 57.8 mg/24 h, matrix score 1.13 ± 0.52, collagen type I score 2.04 ± 0.53, mRNA for collagen type I 227 ± 79% to the group with a single injection of 1-22-3). Although single injection of 5 mg/100 g BW of PAN was not capable of inducing abnormal proteinuria, consecutive injections of 5 mg/100 g BW of PAN and mAb 1-22-3 also caused irreversible mesangial alteration and persistent proteinuria. Conclusions. Podocyte injury might be an important factor that exacerbates mesangial proliferation and mesangial matrix expansion. The irreversible mesangial alterations caused by consecutive injections of PAN and mAb 1-22-3 may be a novel model that could be used to analyze the mechanism of progressive mesangial alteration.
AB - Background. From the observations of morphology seen in early phases of the experimental models of the irreversible mesangial proliferative glomerulonephritis, we hypothesized that podocyte injury is one of the important factors in bringing upon irreversible glomerular alterations. To verify this hypothesis, we investigated whether podocyte injury induced by puromycin aminonucleoside (PAN) injection affects the mesangial alterations of anti-Thy 1.1 glomerulonephritis. Methods. Female Wistar rats were injected with 0.5 mg monoclonal antibody (mAb) 1-22-3 five days after the injection of 10 mg or 5 mg/100 g body weight (BW) of puromycin aminonucleoside (PAN), and sacrificed at 7 days or 8 weeks after the mAb 1-22-3 injection. Results. Consecutive injections of 10 mg/100 g BW of PAN and mAb 1-22-3 caused the irreversible mesangial alteration with persistent proteinuria (at week 8, proteinuria 100.3 ± 57.8 mg/24 h, matrix score 1.13 ± 0.52, collagen type I score 2.04 ± 0.53, mRNA for collagen type I 227 ± 79% to the group with a single injection of 1-22-3). Although single injection of 5 mg/100 g BW of PAN was not capable of inducing abnormal proteinuria, consecutive injections of 5 mg/100 g BW of PAN and mAb 1-22-3 also caused irreversible mesangial alteration and persistent proteinuria. Conclusions. Podocyte injury might be an important factor that exacerbates mesangial proliferation and mesangial matrix expansion. The irreversible mesangial alterations caused by consecutive injections of PAN and mAb 1-22-3 may be a novel model that could be used to analyze the mechanism of progressive mesangial alteration.
UR - http://www.scopus.com/inward/record.url?scp=0035185857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035185857&partnerID=8YFLogxK
U2 - 10.1046/j.1523-1755.2001.00047.x
DO - 10.1046/j.1523-1755.2001.00047.x
M3 - Article
C2 - 11737593
AN - SCOPUS:0035185857
SN - 0085-2538
VL - 60
SP - 2192
EP - 2204
JO - Kidney International
JF - Kidney International
IS - 6
ER -